

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

### **GRANT OF RESTRICTED SHARE UNITS**

On September 30, 2020, the Company granted a total of 14,112 Restricted Share Units (“RSUs”) pursuant to the restricted share unit award scheme (the “RSU Scheme”) adopted by the Company on April 28, 2020 to two eligible grantees (the “Grantees”). The aforementioned granted RSUs represent approximately 0.002% of the issued share capital of the Company as at the date of this announcement. The average closing price of the shares of the Company (the “Share(s)”) for the five business days immediately preceding the date of the grant was HK\$27.46 per Share. Accordingly, the market value of the Shares underlying the RSUs is approximately HK\$387,516.

A summary of the terms of the RSU Scheme was set out in the section headed “Appendix IV – Statutory and General Information – D. Share Incentive Schemes” in the prospectus of the Company dated May 5, 2020. The RSU Scheme does not constitute a share option scheme or an arrangement analogous to a share option scheme for the purpose of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”). Pursuant to the RSU Scheme and the resolutions of the board (the “Board”) of directors (the “Directors”) of the Company, the chairman of the Board was appointed as the authorized administrator who has the authority to administer the RSU Scheme according to the terms and conditions of the RSU Scheme.

The Company has appointed a professional trustee to assist with the administration and vesting of RSUs. The trustee shall make on-market purchases of Shares to satisfy the RSUs granted to the Grantees upon vesting. The Company will provide sufficient funds to the trustee as the Board may in its absolute discretion determine to enable the trustee to satisfy its obligations in connection with the administration and vesting of RSUs granted.

A total of 14,112 RSUs have been granted to two independent non-executive directors of the Company. Further details of the grant are as follows:

<b>Name</b>	<b>Position</b>	<b>Monetary value of RSU grants</b>	<b>Number of RSUs granted</b>	<b>Number of underlying Shares involved</b>
Dr. Stephen Newman OESTERLE (“ <b>Dr. Oesterle</b> ”)	Independent Non-Executive Director	US\$25,000	7,056	7,056
Mr. Robert Ralph PARKS (“ <b>Mr. Parks</b> ”)	Independent Non-Executive Director	US\$25,000	7,056	7,056

The RSUs granted are subject to a vesting schedule, 40% of the RSUs granted shall vest immediately upon granting, 20%, 20% and 20% of the RSUs granted shall vest on the first, second and third anniversary of the respective payment day of the Directors’ compensation.

Pursuant to the service contracts of Dr. Oesterle and Mr. Parks and subject to the terms and conditions of the RSU Scheme and compliance with Listing Rules, they are each entitled to an aggregate total amount of US\$100,000 worth of RSUs per year that shall be granted on a quarterly basis. The number of RSUs to be granted at each quarter shall be calculated as US\$25,000 divided by the higher of either (i) the closing price of the Shares on the relevant payment day, or (ii) the average closing price of the Shares for the five business days immediately preceding the relevant payment day.

As directors of the Company, Dr. Oesterle and Mr. Parks are connected persons of the Company (as defined under the Listing Rules). The grant of RSUs to Dr. Oesterle and Mr. Parks therefore constitutes a connected transaction of the Company under Chapter 14A of the Listing Rules. As the grant of the RSUs to Dr. Oesterle and Mr. Parks forms part of their remuneration package under their respective service contracts as independent non-executive Directors of the Company, such grants on September 30, 2020 and going forward will be exempted from the reporting, announcement and independent shareholders’ approval requirements under Rule 14A.73(6) and Rule 14A.95 of the Listing Rules.

Saved as disclosed above, none of the Grantees is a Director, a chief executive or substantial shareholder of the Company, or any of their respective associates (as defined under the Listing Rules) as at the date of this announcement.

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Suzhou, the People's Republic of China  
October 5, 2020

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Ms. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wayne Wu and Mr. Wai Ming Yip as independent non-executive Directors.*